Novartis Buys Protez For $100M
This article was originally published in The Pink Sheet Daily
Executive Summary
Another $300M due in potential milestone payments on Phase II antibiotic.
You may also be interested in...
Novartis Licenses Worldwide Rights To Paratek's Broad-Spectrum Antibiotic
Clarified regulatory path for antibiotics may have helped produce potentially lucrative deal for the private biotech.
Novartis Licenses Worldwide Rights To Paratek's Broad-Spectrum Antibiotic
Clarified regulatory path for antibiotics may have helped produce potentially lucrative deal for the private biotech.
Wyeth Re-enters Appetite Suppression Game With Thiakis Acquisition
Metabolic disorders is one of six focus areas targeted by Wyeth’s new discovery plan.